Language of the Report – English
Sin embargo, el informe puede estar disponible en español por un costo adicional.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Market Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Latin America
6.2 By Country
7 Industry Opportunities and Challenges
8 Latin America Diabetes Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Latin America Diabetes Drugs Historical Market (2019-2025)
8.3 Latin America Diabetes Drugs Market Forecast (2026-2035)
8.4 Latin America Diabetes Drugs Market by Drugs
8.4.1 Oral Anti-diabetic Drugs
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2019-2025)
8.4.1.3 Forecast Trend (2026-2035)
8.4.1.4 Breakup by Type
8.4.1.4.1 Alpha-Glucosidase Inhibitors
8.4.1.4.2 Biguanides
8.4.1.4.3 Bile Acid Sequestrants
8.4.1.4.4 Dopamine-2 Agonists
8.4.1.4.5 DPP-4 inhibitors
8.4.1.4.6 Meglitinides
8.4.1.4.7 SGLT2 Inhibitors
8.4.1.4.8 Sulfonylureas
8.4.1.4.9 TZDs
8.4.1.4.10 Oral Combination Therapy
8.4.2 Insulin
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2019-2025)
8.4.2.3 Forecast Trend (2026-2035)
8.4.2.4 Breakup by Type
8.4.2.4.1 Insulin Glargine
8.4.2.4.2 Insulin Aspart
8.4.2.4.3 Human Insulin
8.4.2.4.4 Biosimilar Insulin
8.5 Latin America Diabetes Drugs Market by Type
8.5.1 Type 1
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2019-2025)
8.5.1.3 Forecast Trend (2026-2035)
8.5.2 Type 2
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2019-2025)
8.5.2.3 Forecast Trend (2026-2035)
8.6 Latin America Diabetes Drugs Market by Distribution Channel
8.6.1 Online
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2019-2025)
8.6.1.3 Forecast Trend (2026-2035)
8.6.2 Hospital
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2019-2025)
8.6.2.3 Forecast Trend (2026-2035)
8.6.3 Retail Pharmacies
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2019-2025)
8.6.3.3 Forecast Trend (2026-2035)
8.7 Latin America Diabetes Drugs Market by Country
8.7.1 Market Share
8.7.1.1 Brazil
8.7.1.2 Argentina
8.7.1.3 Mexico
8.7.1.4 Others
9 Regional Analysis
9.1 Brazil
9.1.1 Historical Trend (2019-2025)
9.1.2 Forecast Trend (2026-2035)
9.2 Argentina
9.2.1 Historical Trend (2019-2025)
9.2.2 Forecast Trend (2026-2035)
9.3 Mexico
9.3.1 Historical Trend (2019-2025)
9.3.2 Forecast Trend (2026-2035)
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyers Powers
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Key Company Profiles
12.2.1 Novo Nordisk A/S
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Sanofi-Aventis Groupe
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Eli Lilly and Company
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 AstraZeneca plc
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Takeda Pharmaceutical Company Limited
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
13 Industry Events and Developments